Inclusion Criteria:

- Signed written informed consent prior to beginning protocol specific procedures

- Male or female 18 to 75 years of age

- Diagnosis of histologically confirmed adenocarcinoma of the pancreas

- Locally advanced (non-resectable) or metastatic pancreatic cancer

- Presence of at least one uni-dimensional indicator lesion measurable by CT scan or
MRI in not an irradiated area (RECIST criteria)

- Karnofsky performance status of ≥ 70 at study entry

- Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL

- Bilirubin level either normal or < 1.5 x ULN

- ASAT and ALAT ≤ 2.5 X ULN (≤ 5 x ULN if liver metastasis are present)

- Serum creatinine < 1.5 x ULN

- Amylase and lipase ≤ 1.5 x the upper limit of normal

- PT or INR and PTT < 1.5 x upper limit of normal (subjects who receive
anti-coagulation treatment with an agent such as warfarin or heparin will be allowed
to participate provided that no evidence of underlying abnormality in these
parameters exists).

- Effective contraception for both male and female patients if the risk of conception
exists

Exclusion Criteria:

- Brain metastases

- Previous chemotherapy for locally advanced or metastatic pancreatic cancer.

- Adjuvant therapy if documented recurrence is within 6 months after the end of
adjuvant treatment)

- Radiotherapy within 4 weeks prior to study entry

- Major surgery within 4 weeks of first dose of study drug

- Concurrent chronic systemic immune therapy

- Any investigational agent(s) 4 weeks prior to entry

- Clinically relevant coronary artery disease or a history of a myocardial infarction
within the last 6 months

- Thrombotic or embolic events such as cerebrovascular accident including transient
ischemic attacks within the past 6 months

- Acute or subacute intestinal occlusion or history of inflammatory bowel disease

- Known grade 3 or 4 allergic reaction to any of the components of the treatment

- Known drug abuse/ alcohol abuse

- Legal incapacity or limited legal capacity

- Medical or psychological condition which in the opinion of the investigator would not
permit the patient to complete the study or sign meaningful informed consent

- Women who are pregnant or breastfeeding

- Acute or subacute intestinal occlusion

- Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ
of the cervix. (Patients with a previous malignancy but without evidence of disease
for ≥ 5 years will be allowed to enter the trial).